Cardiac Absoludy Cardiac Triple
본문
- Troponin is released during MI from the cytosolic pool of myocytes. Its subsequent release is prolonged with degradation of actin and myosin filaments. Measuring the level of Troponin I is to help to rule out Myocardial Infarction(MI) early. The high specificity of cTnI measurements is beneficial in identifying cardiac injury for clinical conditions involving skeletal muscle injury resulting from surgery, trauma, extensive exercise, or muscular disease.
- NT-proBNP is used as a predictor of Heart Failure (HF). NT-proBNP is typically increased in patients with asymptomatic or symptomatic left ventricular dysfunction and are associated with Coronary Artery Disease (CAD) and myocardial ischemia.
- CK-MB is used to determine if you had a heart attack, the level of it increases 3-4 hours after chest pain in MI patients. Measuring the level of CK-MB is to help detect reinfarction because CK levels return to baseline 36-48 hours after AMI
- By testing NT-proBNP & CK-MB & TnI at once, heart disease can be identified simply and accurately in a short time.
ADVANTAGE
SPECTIFICATION
|
AMR |
TnI_10~2,000 pg/mL |
|
NT-proBNP_15~10,000 pg/mL |
|
|
CK-MK_0.2~50 ng/mL |
|
|
Test time |
5 Min |
|
Samples Type |
Serum and Plasma (Lithiumheparin and K₂-EDTA) |
|
Samples Volume |
100uL |
|
Contact |
Cartridge_20EA |
|
Pretreatment_20EA |
|
|
Disposable Tip_24EA |
|
|
Code Chip_1EA |
|
|
Package Insert_1EA |
RESULT DATA
PROCEDURE
ADVANTAGE
SPECTIFICATION
|
AMR |
TnI_10~2,000 pg/mL |
|
NT-proBNP_15~10,000 pg/mL |
|
|
CK-MK_0.2~50 ng/mL |
|
|
Test time |
5 Min |
|
Samples Type |
Serum and Plasma (Lithiumheparin and K₂-EDTA) |
|
Samples Volume |
100uL |
|
Contact |
Cartridge_20EA |
|
Pretreatment_20EA |
|
|
Disposable Tip_24EA |
|
|
Code Chip_1EA |
|
|
Package Insert_1EA |
RESULT DATA
PROCEDURE
